These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 37632832)

  • 1. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
    Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
    Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
    J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
    Huang X; Wang HF; Huang S
    Front Genet; 2022; 13():906880. PubMed ID: 36061188
    [No Abstract]   [Full Text] [Related]  

  • 9. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs.
    Yang X; Zhang Y; Liu J; Feng Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update.
    He RQ; Huang ZG; Li TY; Wei YP; Chen G; Lin XG; Wang QY
    Cell Physiol Biochem; 2018; 50(4):1474-1495. PubMed ID: 30359990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer.
    Luo WJ; Tian X; Xu WH; Qu YY; Zhu WK; Wu J; Ma CG; Zhang HL; Ye DW; Zhu YP
    J Cell Mol Med; 2021 May; 25(9):4326-4339. PubMed ID: 33797188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma.
    Song J; Sun X; Wang T; Yan L; Su P; Yuan L
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11207-11221. PubMed ID: 37354222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Gao X; Cai J
    Front Genet; 2022; 13():865204. PubMed ID: 35571063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.